Aclaris Therapeutics' (ACRS) Sell (E+) Rating Reiterated at Weiss Ratings

Key Points

• Aclaris Therapeutics' stock received a reiterated "sell (e+)" rating from Weiss Ratings, amidst mixed sentiments from other analysts, including a "buy" rating from HC Wainwright with a $16.00 price target.
• The company's stock has seen a decline of 7.6% recently, trading at $1.77, while analysts project a consensus price target of $8.71 based on average ratings.
• Aclaris Therapeutics reported a quarterly loss of ($0.13) earnings per share, meeting expectations, and had revenues of $1.78 million exceeding analyst predictions.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by stock analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on ACRS. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, June 25th. Piper Sandler began coverage on shares of Aclaris Therapeutics in a research note on Thursday, July 10th. They issued an "overweight" rating and a $6.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and issued a $8.00 price objective on shares of Aclaris Therapeutics in a research note on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $8.71.

Aclaris Therapeutics Trading Down 7.6%

Shares of ACRS stock traded down $0.15 on Tuesday, reaching $1.77. 946,313 shares of the stock were exchanged, compared to its average volume of 968,332. The business's 50 day moving average price is $1.86 and its 200 day moving average price is $1.56. The company has a market capitalization of $191.20 million, a price-to-earnings ratio of -1.29 and a beta of 0.26. Aclaris Therapeutics has a twelve month low of $1.05 and a twelve month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $1.78 million during the quarter, compared to analysts' expectations of $1.34 million. Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%. Equities research analysts forecast that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Aclaris Therapeutics

Several hedge funds have recently bought and sold shares of ACRS. Squarepoint Ops LLC increased its position in shares of Aclaris Therapeutics by 11.9% in the second quarter. Squarepoint Ops LLC now owns 390,583 shares of the biotechnology company's stock valued at $555,000 after buying an additional 41,666 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Aclaris Therapeutics by 53.5% in the second quarter. Bridgeway Capital Management LLC now owns 443,319 shares of the biotechnology company's stock valued at $630,000 after purchasing an additional 154,600 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Aclaris Therapeutics by 10.5% in the second quarter. Raymond James Financial Inc. now owns 277,259 shares of the biotechnology company's stock valued at $394,000 after purchasing an additional 26,454 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $70,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $48,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.